Share This! Tweet This! Recommend Us! Print Page

Public Current Cancer Trials

Find a Doctor
Find a Location

Participate in One of These Clinical Trials

Bone Metastases

(Observational)

A prospective observational Multicenter Cohort Study to Assess the Incident of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment.

Click for Protocol Summary


Brain

RTOG 0834 - (Anaplastic Glioma)

Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial.

Click for Protocol Summary

CTSU A221101: The Use of Armodafinil (Nuvigil) to Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiform: A Randomized, Novel Adaptive Design Study.

Click for Protocol Summary

A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain.

ClinicalTrials.gov Identifier: NCT01351519

Please Contact:
Christine Goetz, BA, CCRC
253-403-7193;
Pager 253-305-1189

Breast

SCCA 6628
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed by Bevacizumab and Erlotinib in Treating Patients With Metastatic Breast Cancer

Click for Protocol Summary

Please Contact:
Christine Goetz, BA, CCRC
253-403-7193;
Pager 253-305-1189

NSABP B-43
A Phase III Clinical Trial Comparing Trastuzumab given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In situ Resected by Lumpectomy.

Click for Protocol Summary

HLMCC 0806
(Adjuvant OR Neoadjuvant)
Phase II placebo-controlled trial of lisinopril and Coreg to reduce cardiotoxicity in patients with breast cancer receiving (neo) adjuvant chemotherapy with trastuzumab (Herceptin).

Click for Protocol Summary


PRESENT-Vaccine Trial
Prevention of Recurrence in Early Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVaxTM Treatment.

Click for Protocol Summary

Please Contact:
Christine Goetz, BA, CCRC
Phone: 253-403-7193
Pager: 253-305-1189

E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patents with Metastatic Breast Cancer

Click for Protocol Summary

SWOG 1007-QOL closed
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

Click for Protocol Summary

NSABP B-47
A Randomized Phase III Trial of Adjuvant Therapy Comparing
Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.

Click for Protocol Summary


NSABP B-49
A Phase III Clinical trial comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.

Click for Protocol Summary


PRESENT-Vaccine Trial
Prevention of Recurrence in Early Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVaxTM Treatment.

Click for Protocol Summary

Contact:
Christine Goetz, BA, CCR
Phone: 253-403-7193
Pager: 253-305-1189

Gastrointestinal

CALGB 80702
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.

Click for Protocol Summary

LCCC 1029
A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) versus Placebo with FOLFIRI as Second-Line Therapy in Patients with Metastatic Colorectal Cancer.

Click for Protocol Summary

Contact:
Christine Goetz, BA, CCRC
Phone: 253-403-7193
Pager: 253-305-1189

RTOG 0848
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

Click for Protocol Summary

RTOG 1010
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Click for Protocol Summary

S1201
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer.

Click for Protocol Summary

Genitourinary

SWOG 1014
Abiraterone Acetate Treatment for Prostate Cancer patients with a PSA of More than Four Following Initial Androgen Deprivation Therapy, Phase II.

Click for Protocol Summary

RTOG 0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer.

Click for Protocol Summary

RTOG 0534
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy.

Click for Protocol Summary

CALGB 70807
The Men's Eating and Living (MEAL) Study: A Randomized Trial of diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance.

Click for Protocol Summary

SWOG 0931
Everest: Everolimus for Renal Cancer Ensuring Surgical Therapy, a Phase III Study

Click for Protocol Summary

E2810
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.

Click for Protocol Summary

CALGB 90601
A randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in patients with advanced transitional cell carcinoma (TCC).

Click for Protocol Summary

N1048
A phase II/III trial of Neoadjuvant FOLFOX, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision.

Click for Protocol Summary


Gynecologic

RTOG 0724
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy.

Click for Protocol Summary

GOG 0262
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer.

Click for Protocol Summary

Contact:
Christine Goetz, BA, CCRC
Phone 253-403-7193
Pager 253-305-1189

GOG 213
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC#704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian,Peritoneal Primary and Fallopian Tube Cancer.

Click for Protocol Summary

Contact:
Christine Goetz, BA, CCRC
Phone 253-403-7193
Pager 253-305-1189
MULTICARE CLINIC ONLY

GOG 212
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or XyotaxTM (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.

Click for Protocol Summary

Contact:
Christine Goetz, BA, CCRC
Phone 253-403-7193
Pager 253-305-1189
MULTICARE CLINIC ONLY

GOG 0186J
A randomized phase IIB evaluation of weekly Paclitaxel plus PazopanIB versus weekly Pacliataxel plus placebo in the treatment of persistent or recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carconoma.

Click for Protocol Summary

Contact: Christine Goetz, BA, CCRC
Phone: 253-403-7193
Pager: 253-305-1189

AMG 386
A phase III randomized, double-blind, placebo-controlled, multi-center stdy of AMG 386 with Paclitaxel and Carboplatin as first-line treatment of subjects with stage III-IV epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Click for Protocol Summary

Contact:
Christine Goetz, BA, CCRC
Phone: 253-403-7193
Pager: 253-305-1189

GOG 0258
A Randomized Phase III Trial of Cisplatin and tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carconoma.

Click for Protocol Summary

Please Contact:
Christine Goetz, BA, CCRC
253-403-7193;
Pager 253-305-1189

Head and Neck

R1016
Phase III Trial of radiotherapy plus cetusximab versus chemoradiotherapy in hpv-associated oropharynx cancer.

Click for Protocol Summary


Liver

CALGB 80802
Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).

Click for Protocol Summary

E1208
A Phase III Randomized, Double Blind Trial of Chemoembolization with or without Sorefenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion.

Click for Protocol Summary

Lung

ACCURAY-ACCL001.1
(Cyberknife)
A prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer.
Contact:
Samantha Elliott
253-403-2319

ECOG 5508
Randomized Phase III Study of Maintenance Therapy with Bevacizumab Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advance Non-Squamous NSCLC.

Click for Protocol Summary

SWOG 0819
A Randomized Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without concurrent Cetuximab in patients with advanced non-small cell lung cancer.

Click for Protocol Summary

C30801
A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer.

Click for Protocol Summary

SCCA 7755 A Phase II study of weekly Abraxane (nab-paclitaxel) for patients with advanced NSCLC with EGFR mutations following front-line therapy with EGFR tyrosine kinase inhibitors

Please Contact:

Christine Goetz, BA, CCRC

Phone: 253-403-7193

Pager: 253-305-1189


Leukemia

PSOC 2301
A Phase II Study of Bexxar Consolidation in Patients with B-Cell Chronic Lymphocytic Leukemia Following Fludarabine and Rituximab Chemotherapy.

Please Contact:
Christine Goetz, BA CCRC
Phone: 253-403-7193
Pager: 253-305-1189

Melanoma

ECOG 1609
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-risk Melanoma.

Click for Protocol Summary

Multiple Myeloma

E3A06
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma.

Click for Protocol Summary


For More Information